Declining competitive advantage due to alternative technologies and new competitor entry
First written in FY2016. 3 of 6 entries say "Restated". Latest entry: 2026-06-29.
No other company in this theme has enough history to compare yet.
- FY2020RestatedAnnual report
「However, if superior substitute technologies or technologies with greater price competitiveness are developed in the future and the Group loses its technological advantage, its technology could become obsolete or be exposed to price competition.」
The risk of a decline in PXB mice's competitive advantage due to substitute technologies and price competition is being reassessed. - FY2018RestatedAnnual report
「However, if superior substitute technologies or technologies with greater price competitiveness are developed in the future and the Group loses its technological advantage, its technology could become obsolete or be exposed to price competition.」
The risk of a decline in PXB mice's competitive advantage due to substitute technologies and price competition is being reassessed. - FY2017RestatedAnnual report
「Stable production of the PXB mouse business's core technology, the “chimeric mouse with human hepatocytes,” requires a high level of technical capability and know-how based on production experience, and the Group therefore believes that barriers to entry are high. However, as market expansion is expected, other companies may enter the market in the future.」
In addition to substitute technologies, the disclosure explicitly identifies competition from new entrants and price competition as risks. - FY2016First statedAnnual report
「PXB mice, the Group's main product, have a human hepatocyte replacement rate of 70% or higher, and the Group recognizes them as an effective technology for drug development. However, if superior substitute technologies or technologies with greater price competitiveness are developed in the future and the Group loses its technological advantage, its technology could become obsolete or be exposed to price competition.」
While presenting a replacement rate of 70% or higher as a competitive advantage, the disclosure identifies substitute technologies, price competition, and new market entrants as risks.